Spectrum and Management of Complement Immunodeficiencies (Excluding Hereditary Angioedema) Across Europe

Journal of Clinical Immunology

Volumn 35, Issue 2, 2015, Pages 199-205

  Turley, A J ^a   Gathmann, B ^b   Bangs, C ^c   Bradbury, M ^d   Seneviratne, S ^e   Gonzalez Granado, L I ^f   Hackett, S ^g   Kutukculer, N ^h   Alachkar, H ⁱ   Hambleton, S ^j   Ritterbusch, H ^b   Kralickova, P ^k   Marodi, L ^l   Seidel, M G ^m   Dueckers, G ⁿ   Roesler, J ^o   Huissoon, A ^p   Baxendale, H ^q   Litzman, J ^r   Arkwright, P D ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g Birmingham Heartlands   (United Kingdom)

^h EGE UNIVERSITY   (Turkey)

ⁱ SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^j NEWCASTLE UNIVERSITY   (United Kingdom)

^k Inst Clin Immunology/Allergology   (Czech Republic)

^l UNIVERSITY OF DEBRECEN   (Hungary)

^m MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁿ Children's Hospital Krefeld   (Germany)

^o DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^p BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^q ADDENBROOKE S HOSPITAL   (United Kingdom)

^r ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

more..

Author keywords

antibiotics; atypical hemolytic uremic syndrome; Complement; glomerulopathy; immunodeficiency; meningococcemia; Streptococcus pneumoniae; vaccination

Indexed keywords

ANTIBIOTIC AGENT; COMPLEMENT FACTOR; IMMUNOSUPPRESSIVE AGENT; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; COMPLEMENT;

ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOIMMUNITY; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL FEATURE; CLINICAL IMMUNOLOGY; CLINICAL LABORATORY; COMPLEMENT DEFICIENCY; COMPLEMENT IMMUNODEFICIENCY; EUROPE; FAMILY HISTORY; FEMALE; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HOMOZYGOSITY; HUMAN; IMMUNE DEFICIENCY; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MENINGOCOCCEMIA; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REGISTER; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION; AGED; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONSANGUINITY; DEFICIENCY; DISEASE MANAGEMENT; FACTUAL DATABASE; GENETICS; GENOTYPE; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; CONSANGUINITY; DATABASES, FACTUAL; DISEASE MANAGEMENT; EUROPE; FEMALE; GENOTYPE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84925534410     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-015-0137-5     Document Type: Article

References (40)

1. Grumach AS, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol. 2014;61:110–7.
2. Aghamohammadi A, Mohammadinejad P, Abolhassani H, Mirminachi B, Movahedi M, Gharagozlou M, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol. 2014;34:478–90.
3. Zelazko M, Carneiro-Sampaio M, de Luigi Cornejo M, de Olarte Garcia D, Porras Madrigal O, Berron Perez R, et al. Primary immunodeficiency diseases in Latin America: first report from eight countries participating in the LAGID. Latin American Group for Primary Immunodeficiency Diseases. J Clin Immunol. 1998;18:161–6.
4. Dommett RM, Klein N, Turner MW. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens. 2006;68:193–209.
5. Khan S, Tarzi MD, Doré PC, Sewell WA, Longhurst HJ. Secondary systemic lupus erythematosus: an analysis of 4 cases of uncontrolled hereditary angioedema. Clin Immunol. 2007;123:14–7.
6. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–97.
7. Polley MJ. Inherited c’2 deficiency in man: lack of immunochemically detectable c’2 protein in serums from deficient individuals. Science. 1968;161:1149–51.
8. Alper CA, Abramson N, Johnston RB, Jandl JH, Rosen FS. Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med. 1970;282:350–4.
9. Torisu M, Sonozaki H, Inai S, Arata M. Deficiency of the fourth component of complement in man. J Immunol. 1970;104:728–37.
10. Miller ME, Nilsson UR. A familial deficiency of the phagocytosis-enhancing activity of serum relates to a dysfunction of the fifth component of complement (C5). N Engl J Med. 1970;282:354–8.
11. Moncada B, Day NK, Good RA, Windhorst DB. Lupus-erythematosus-like syndrome with a familial defect of complement. N Engl J Med. 1972;286:689–93.
12. Petersen BH, Lee TJ, Snyderman R, Brooks GF. Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency. Ann Intern Med. 1979;90:917–20.
13. Lewis LA, Ram S. Meningococcal disease and the complement system. Virulence. 2014;5:98–126.
14. Gaschignard J, Levy C, Chrabieh M, Boisson B, Bost-Bru C, Dauger S, et al. Invasive pneumococcal disease in children can reveal a primary immunodeficiency. Clin Infect Dis. 2014;59:244–51.
15. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508–30.
16. Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ. New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep 2014;34(5).
17. Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol. 2013;56:199–212.
18. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis–a new look at an old entity. N Engl J Med. 2012;366:1119–31.
19. Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82:454–64.
20. Wen L, Atkinson JP, Giclas PC. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol. 2004;113:585–93.
21. Rodriguez-Marco A, Bradbury M, Riley P, Arkwright PD. Autoimmunity and recurrent infections in partial complement C3 immunodeficiency. Rheumatology (Oxford). 2010;49:1017–9.
22. Arkwright PD, Riley P, Hughes SM, Alachkar H, Wynn RF. Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2014;133:265–7.
23. Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol. 2004;15:787–95.
24. Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int. 2010;77:339–49.
25. Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey MA, Bordereau P, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood. 2012;119:4182–91.
26. Boteva L, Morris DL, Cortés-Hernández J, Martin J, Vyse TJ, Fernando MM. Genetically determined partial complement C4 deficiency states are not independent risk factors for SLE in UK and Spanish populations. Am J Hum Genet. 2012;90:445–56.
27. Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62–73.
28. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.
29. Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med. 2012;366:1165–6.
30. Platonov AE, Vershinina IV, Kuijper EJ, Borrow R, Käyhty H. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine. 2003;21:4437–47.
31. Gomez-Lus ML, Giménez MJ, Vázquez JA, Aguilar L, Anta L, Berrón S, et al. Opsonophagocytosis versus complement bactericidal killing as effectors following Neisseria meningitidis group C vaccination. Infection. 2003;31:51–4.
32. Brown JS, Hussell T, Gilliland SM, Holden DW, Paton JC, Ehrenstein MR, et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A. 2002;99:16–969.
33. Yuste J, Sen A, Truedsson L, Jönsson G, Tay LS, Hyams C, et al. Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect Immun. 2008;76:3761–70.
34. Alba-Domínguez M, López-Lera A, Garrido S, Nozal P, González-Granado I, Melero J, et al. Complement factor I deficiency: a not so rare immune defect: characterization of new mutations and the first large gene deletion. Orphanet J Rare Dis. 2012;7:42.
35. Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol. 2013;735:155–72.
36. Ambati J, Atkinson JP, Gelfand BD. Immunology of age-related macular degeneration. Nat Rev Immunol. 2013;13:438–51.
37. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the advisory committee on immunization practices. Morbidy and Mortality weekly report. 2013; 62:2.
38. Ladhani SN, Cordery R, Mandal S, Christensen H, Campbell H, Borrow R, et al. Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero(®)). J Infect. 2014;69:470–80.
39. Kuruvilla M, de la Morena MT. Antibiotic prophylaxis in primary immune deficiency disorders. J Allergy Clin Immunol Pract. 2013;1:573–82.
40. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V, French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643–57.